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ABSTRACT 
Methacholine (MCh) and mannitol challenges are tests used to assess airway 
responsiveness. It has been shown that airway responsiveness to direct 
bronchoconstrictors like MCh tends to increase following exposure to allergen but the 
response to mannitol an indirect stimuli, is not known. Furthermore, the provocative 
concentration causing a 20% decrease in Forced Expiratory Volume in one second (FEV1) 
for adenosine 5’ monophosphate (AMP) correlates better to sputum eosinophilia than MCh 
PC 20. Hence, we hypothesized that airway responsiveness will be greater when measured 
with mannitol than MCh. We studied airway responsiveness to MCh and mannitol first at 3 
hours and then later at 24 hours after allergen challenge. The 3-hour study yielded results 
contrary to our hypothesis therefore a twenty-four hour study was undertaken. Ten mild 
atopic asthmatics who had a positive MCh challenge and an allergic response to allergen 
extracts such as cat, horse, and house dust mite completed the 3-hour study. Eleven mild 
atopic asthmatics with the criteria above completed the 24-hour study. Both studies were 
non-blinded, randomized clinical trials. Airway responsiveness to MCh was quantitated by 
changes in PC20.  Airway responsiveness to mannitol was quantitated as PD15 in the 3-hour 
study and dose response ratio (DRR) in the 24-hour study. In both studies, the allergen 
challenges were separated by 14 days. Fractional exhaled nitric oxide measurements 
(FENO) were collected in both studies at varying time points to track airway inflammation. 
In the 3-hour study, the geometric mean MCh PC20 decreased significantly after allergen 
exposure from 0.88 mg/ml to 0.50 mg/ml (p = 0.02) indicating airway responsiveness to 
MCh increased.  Conversely, the geometric mean mannitol PD15 increased significantly 
from 174 mg to 284 mg (p =0.02) indicating a decrease in airway responsiveness to 
mannitol. In the 24-hour study, the geometric mean MCh PC20 again decreased 
significantly from 5.9 mg/ml to 2.2 mg/ml (p= 0.01) after allergen exposure. The mannitol 
DRR increased significantly from 63 mg/∆%FEV1 to 158 mg/∆%FEV1 (p = 0.03).  FENO 
levels increased significantly in MCh arm but not mannitol arm. That is pre allergen 
challenge versus 24 hours after allergen challenge (for MCh arm: 26 ppb pre to 55 ppb 
post; for mannitol arm: 31 ppb pre to 39 ppb post).  In conclusion, at three and twenty-four 
hours after allergen challenge, a time when the airways are more responsive to MCh, there 
is a significant decrease in airway responsiveness to mannitol. 
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1.   ASTHMA – AN OVERVIEW 
1.1   Introduction 
According to the Global Initiative for Asthma (GINA), asthma is a chronic 
inflammatory disorder of the airways associated with airway hyperresponsiveness 
(AHR), leading to recurrent episodes of wheezing, breathlessness, chest tightness, and 
coughing. A major characteristic of asthma is spontaneously reversible airflow 
obstruction or resolvable airway obstruction with treatment [Global Initiative for Asthma, 
2014].  
The complexity of asthma and the incomplete knowledge of asthma have caused 
an evolving standard for the classification of asthma into phenotypes and endotypes 
[Corren, 2013]. An example of a phenotype of asthma is eosinophilic asthma. The 
eosinophilic phenotype includes allergic asthma, aspirin sensitive asthma, and severe-
late-onset hyper-eosinophilic asthma. Another asthma phenotype is poor steroid 
responsive asthma. This phenotype of asthma includes non-eosinophilic (neutrophilic) 
asthma, steroid-insensitive eosinophilic asthma, and airflow obstruction caused by 
obesity endotypes [Lötvall et al., 2011]. Asthma can be broadly classified into two main 
groups, namely, extrinsic (atopic) and intrinsic (non-atopic).Extrinsic asthma is triggered 
by allergens. In the extrinsic asthma, the immune system “overacts” in exerting a 
protective mechanism in response to harmless substances such as pollen. The 
causative mechanism for intrinsic asthma is unknown although extremes of emotions, 
contact with chemicals or exercises are known to cause intrinsic asthma. These agents 
stimulate the response of nerves in the airways culminating into the symptoms of 
asthma. Knowing the type or classification of asthma greatly influences the treatment.  
The two main therapeutic effects sought after in asthma are the relaxation of 
airway smooth muscle (bronchodilation) and suppression of airway inflammation 
depending on disease severity [Rabe et al., 2006]. Bronchodilators act through the 
sympathetic adrenergic neuroendocrine pathways, which cause a depletion of 
intracellular calcium and a decrease in contractile force leading to smooth muscle 
relaxation [Knox et al., 1995]. Anti-inflammatory therapy targets the pathophysiological 
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mediators that contribute to the exacerbation of asthma inflammation. The anti-
inflammatory therapies include antihistamines, lipooxygenase inhibitors, leukotriene 
antagonists [Cobanoglu et al., 2013], inhaled corticosteroids and mast cell stabilizers.    
 
Asthma is one of the most chronic diseases in the Canadian population. Asthma 
affects 2.4 million Canadians over the age of 12 (8.5 percent of the population) and 
other 490 000 children between the ages of 4 and 11 [Government of Canada, Statistics 
Canada, 2010; Government of Canada Public Health Agency of Canada, 2007]. 
According to doctors, fifty-three percent of Canadians with asthma poorly control the 
disease [Chapman et al., 2008]. Asthma is more prevalent among First Nations, Inuit, 
and Metis communities than in the general Canadian population by a margin of 40 
percent [Tait, 2008]. About 250 deaths from asthma are recorded yearly within the 
Canadian population [Rowe, 2010].Asthma and allergies affect the lives of many 
people, both in the low–income and high-income countries. WHO admits that asthma is 
a public health problem, however complete pathology of asthma is not known; as such, 
there is the need for research into allergic diseases especially asthma. Uncovering the 
group of population susceptible to a specific type of asthma can help track the causes, 
diagnosis and possible treatment of asthma. This can help the government to allocate 
resources and help fund researches specific for a population. For example if a specific 
pollen or chemical in the environment is causing an increase in a specific type of 
asthma, the appropriate steps will be taken to curtail the outbreak. The different types of 
asthma cannot be detected by a single test, hence the need to have more tests to help 
distinguish the different types of asthma and indicate the course of treatment for the 
asthma type. Allergic asthma happens to be a good model for elucidating the 
pathogenesis of asthma and producing new therapeutic strategies for asthma. For the 
purpose of this research study, more emphasis is put on allergic asthma. 
1.2 .   Atopic Asthma 
The American Academy of Allergy, Asthma and Immunology regards atopic 
asthma as the genetic tendency to develop allergic disease (asthma). An important 
feature of atopy is a heightened immune response to inhaled allergens. A cumulative 
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effect on the immune response to a sensitized allergen is the contraction, inflammation, 
and subsequent narrowing of the airways. These symptoms manifest as coughing, 
wheezing, and other asthmatic symptoms [American Academy of Allergy Asthma and 
Immunology, 2014]. An IgE response to allergenic proteins prompts the emergence of 
allergic airway inflammation [Platts-Mills, 2001]. The proteins cross link high affinity IgE 
receptors (FԐRI) on mast cells, which cause degranulation. Activation and degranulation 
of mast cells lead to the release of a variety of bronchoconstricting mediators such as 
histamines, leukotrienes (LTC4), and pro-inflammatory prostaglandins.   
1.2.1.   Airway responses in allergen inhalation challenge 
Allergen challenges are primarily employed in research regarding cellular and 
humoral mechanisms that surround the nature of allergen induced airway responses. 
Allergen inhalational challenges involve exposing the participant to an allergen. The 
participant is usually sensitized to the allergen before the laboratory exposure. The 
inhalation of allergen results in the subsequent activation of secretory pathways leading 
to the release of preformed and newly generated mediators of bronchoconstriction and 
vascular permeability [Gauvreau et al., 2007]. Airway response is grouped according to 
the period that the symptoms of bronchoconstriction appear. The airway responses are 
categorized into early asthmatic response and late asthmatic response. 
 
1.2.2.   Early Asthmatic Response 
The early asthmatic response describes an episode of bronchoconstriction 
occurring within 10 minutes of allergen exposure. EAR usually resolves spontaneously 
in 2 to 3 hours or sooner with treatment. EAR is the easiest allergen response to identify 
in a clinical setting due to its clinical symptoms occurring shortly after exposure to 
inhaled allergens. All allergic asthmatics have an EAR. EAR depends largely on the 
release of mediators from mast cells of the airways hence, EAR can be blocked by 
nedocromil, cromoglycate (mast cell stabilizers) and salbutamol (beta 2 agonists) 
[Cockcroft et al., 1987a]. 
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1.2.3.   Late Asthmatic Response    
The late asthmatic response (LAR) describes an episode of recurrent 
bronchoconstriction, occurring between three and eight hours following allergen 
exposure. The LAR occurs in about half of people with a positive allergen challenge. 
LAR is closely associated with allergen-induced eosinophilic airway inflammation lasting 
up to several days [Pin et al., 1992]. In some severe cases, the LAR may not be fully 
abolished with just bronchodilators. This suggests that either cellular or non-cellular 
aspects of inflammation are also involved in the pathogenesis of asthma [Cockcroft et 
al., 1987a]. LAR causes the influx and activation of inflammatory cells, particularly 
lymphocytes and eosinophils in the bronchial mucosa [Robinson et al., 1993]. As such, 
nedocromil, cromoglycate (mast cell stabilizers) and steroids [Cockcroft et al., 1987a] 
can also abolish the LAR. The figure below (figure 1.1) shows a sample of the early and 
late asthmatic responses. 
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Figure 1.1. Graphical representation of the early and late asthmatic response 
assessed as percent decrease in FEV1 
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1.2.4. Sequelae: Increased airway responsiveness and inflammation 
According to the guidelines for diagnosis and management of asthma, airway 
inflammation and hyperresponsiveness are recognized as major characteristics of 
bronchial asthma [U S Department of Health and Human services, National Institutes of 
Health, National Heart, Lung and Blood Institute Expert Panel Report, 2007]. However, 
the relationship between airway inflammation, hyperresponsiveness, remodeling of the 
airway walls and their connection to airway smooth muscle in asthma is not clear 
[Holgate et al., 2008]. A key defining characteristic of asthma is airway 
hyperresponsiveness (AHR) to direct acting stimuli like methacholine [Hargreave et al., 
1981]. 
 Allergen exposure causes an increase in airway responsiveness consistent with 
the recruitment of inflammatory cells in the airways [Brusasco et al., 1990]. This 
suggests that there may be a relationship between airway hyperresponsiveness and 
airway inflammation [Kirby et al., 1987; Bradley et al., 1991]. On the other hand, Crimi et 
al., argue a dissociation between airway inflammation and airway hyperresponsiveness 
in allergic asthma [Crimi et al., 1998]. Allergic asthma is dependent on the presence of 
IgE antibodies specific to allergens in the lungs. Upon sensitization of an individual to a 
particular antigen, future encounters with the allergen cause the crosslinking of IgE 
bound to the high affinity IgE receptor FcɛRI. The crosslinking of IgE stimulates the 
release of pre-formed mediators, and the newly generated mediators responsible for the 
early allergic response. A later reaction (late allergic response) may result from the 
subsequent release of cytokines and chemokines that recruit macrophages, 
eosinophils, and basophills [De Monchy et al., 1985; Durham et al., 1988; Macfarlane et 
al., 2000]. 
Allergic asthma is widely believed to be triggered by T-helper type two (TH2) 
lymphocytes of the immune system. The TH2 cell pathway is initiated by the uptake of 
allergens by antigen presenting cells (APCs). The APCs present selected peptides to 
naïve T cells, by directing them in favor of TH2 cell phenotype that mediates cytokine 
secretion [Hammad et al., 2006]. Dendritic cells (DCs) are responsible for initiating and 
maintaining allergic TH2 cell response to inhaled allergens in asthma [Hammad et al., 
2008]. TH2 cells induce the survival and recruitment of eosinophils and mast cells. In 
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addition to the bronchial hyperreactivity, goblet cell hyperplasia, degranulation of 
mucus-secreting cells, micro-vascular remodeling, leakage, and chemo-attraction of 
inflammatory cells is also induced. These changes lead to potentiation of inflammation 
and contribute to some of the characteristics of asthma, including sputum production, 
airway narrowing, exacerbations and accelerated loss of lung function [Rose et al., 
1997, Fahy et al., 1998]. These changes in bronchial hyperreactivity are via excitability 
of bronchial smooth muscle cells, in response to various nonspecific stimuli such as 
cold air or physical exercise [Hammad et al., 2008]. TH2 cell-mediated inflammation in 
asthmatic airways is suppressed by corticosteroids through the inhibition of expression 
of cytokines, chemokines, and adhesion molecules [Barnes et al., 1998].  
Bronchoconstriction in asthma can also happen via degranulation of mast cells 
and production of TH2 cell associated cytokines. These processes by mast cells occur 
in the smooth muscle layer surrounding the airway wall [Brightling et al., 2002]. B cells 
are key immunological cells that help in capturing and processing allergens [von Garnier 
et al., 2007]. T cells on the other hand, help coordinate the up-regulation and 
expression of cytokines that include interleukin-3 (IL-3), IL-4, IL-5, IL-9, IL-13 and 
granulocyte/macrophage colony-stimulating factor (GM-CSF) [Cousins et al., 2002]. 
These cytokines are involved in IgE synthesis of B-cell switching (IL-4 and IL-13), mast 
cell recruitment (IL-4, IL-9 and IL-13), eosinophil maturation (IL-3, IL-5 and GM-CSF) 
and basophils (IL-3 and IL-4). Basophils are also mediator-secreting effector cells of the 
allergic response [Holgate et al., 2008]. The recent discovery of another subset of CD4+ 
cells (regulatory T cells TREG) has affected and driven research into allergic diseases. 
TREG cells have been strongly implicated in the suppression of allergic responses 
[Bachetta et al., 2007]. TREG cells also control TH2 cell responses in humans through 
cytokines IL-10, and transforming growth factor-β (TGF−β) [Larche et al., 2007]. 
1.3. Bronchoprovocation with direct acting stimuli  
Bronchoprovocation tests are done with the aim of causing bronchoconstriction 
via airway challenge tests with a stimulus. The direct acting stimuli provoke airway 
smooth muscle contraction by activating smooth muscle cell receptors. These kinds of 
stimuli include histamine, leukotrienes, and muscarinic agonists like methacholine. The 
6 
 
indirect stimulus involves intermediate steps leading to bronchoconstriction due to the 
release of mediators from inflammatory cells such as mast cells [Pauwels et al., 1988]. 
Unlike direct stimuli, indirect stimuli do not interact physically with airway smooth muscle 
receptors. Although both stimuli results in bronchoconstriction, they do so in different 
pathways. 
1.3.1. Methacholine 
Methacholine is a synthetic choline ester that acts as muscarinic receptor 
agonists in the parasympathetic nervous system. As a parasympathetic agent, 
methacholine reverses bronchodilation. In the case of an asthmatic airway, 
methacholine causes bronchoconstriction hence its use to diagnose bronchial 
hyperreactivity. The presence of a methyl group on methacholine makes it sensitive to 
muscarinic receptors as compared to nicotinic receptors hence it has little effect on 
nicotinic receptors and does not cross the blood brain barrier. It is resistant to 
acetylcholineterase hence it is broken down at a slower rate in the body. Adverse 
effects of methacholine are mostly cardiovascular that is bradycardia and hypotension, 
as such a preference for its use in the airways. 
 
A 20% fall from a baseline FEV1 at a methacholine concentration less than 16 
mg/ml is considered a positive methacholine challenge [Crapo et al., 2000]. The 
provocation concentration of methacholine causing a 20% fall in FEV1 is termed 
methacholine PC20 (MCh PC20). MCh PC20 is distributed in a normal log fashion in the 
population, with no sharp cut-point between normal participants without asthma and 
asthmatic participants. The methacholine challenge test involves a doubling 
methacholine concentration administered at a fixed five-minute interval. Within the five-
minute interval, a known concentration of methacholine is administered followed by the 
measurement of FEV1. The results are expressed as MCh PC20. The methacholine test 
has a high negative predictive value; hence, a MCh PC20 greater than 16 mg/ml 
excludes asthma in some circumstances. Methacholine challenge testing is more useful 
in excluding a diagnosis of asthma rather than establishing the presence of asthma. 
This is because the methacholine challenge test has a greater negative predictive 
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power than positive predictive power [Crapo et al., 2000]. Furthermore, methacholine 
tests are highly sensitive but not specific for asthma diagnosis. 
1.4. Bronchoprovocation with indirect stimuli  
Indirect stimuli include physical stimuli such as; exercise and cold air, chemical 
stimuli such as adenosine 5’ monophosphate (AMP) and mannitol, inhaled particulate 
irritants and sensitizing stimuli such as allergens. Mannitol is an osmotic indirect 
stimulus. Indirect stimulus requires a relatively high dose of the stimulus to provoke 
bronchoconstriction when compared to direct stimuli. Natural occurring asthma involves 
exposure to indirect agents of bronchoconstriction; hence, indirect airway 
responsiveness is specific for asthma activity and inflammation. One could argue that a 
positive indirect challenge such as a positive exercise challenge can be used as a 
diagnosis or an inclusion criterion for asthma. Moreover, indirect challenges show a 
better correlation with airway eosinophils than direct challenges. Although both AMP 
PC20 and MCh PC20 correlate with airway eosinophils, it has been shown that AMP 
PC20 correlates better with airway inflammation level than MCh PC20 [van den Berge et 
al., 2001a]. Indirect challenges have a high level of specificity and positive predictive 
value; hence, indirect challenges tend to complement direct challenges. Direct stimuli 
(methacholine) are better at ruling out asthma while indirect stimuli (mannitol, AMP, 
EIB) are better at predicting the presence of asthma. Since it is known that airway 
hyperresponsiveness to direct stimuli changes after allergen challenge, we will like to 
know what happens to indirect stimuli in a similar circumstance.  
1.4.1. Exercise Induced Bronchoconstriction (EIB) 
 
Exercise does not cause asthma: however, it is a frequent trigger. The lack of specific 
symptoms makes it difficult to diagnose EIB because the symptoms could be seen as a 
manifestation of vigorous exercise. Methacholine and mannitol are pharmacological 
agents used for the diagnosis of EIB. Methacholine challenge test have a lower 
sensitivity to EIB as compared to mannitol. EIB is closer to mimicking the asthma in a 
real case scenario as such attention is paid to how closer methacholine and mannitol 
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are at diagnosing EIB. Secondly, since mannitol is a newer diagnostic tool for asthma, 
researchers like to compare its performance with methacholine in different conditions 
that mimic asthma. 
 
EIB describes the brief narrowing of the airways following participation in 
vigorous exercise. This condition is present in both asthma patients and non-asthma 
patients [Freed et al., 2008]. Clinically, EIB is characterized by a post exercise decrease 
between 10% and 15% in forced expiratory volume in one second (FEV1) of the pre-
exercise FEV1 [Anderson et al., 2010]. Although spontaneous recovery of the FEV1 
occurs within 30 to 60 minutes following an EIB episode, half of the individuals become 
refractory to a repeated exercise stimulus within 4 hours [Freed et al., 2008]. EIB is 
among the first symptoms to appear and the last symptoms to disappear with treatment 
[Porsbjerg et al., 2005]. Scuba divers are among sport individuals whom the diagnosis 
of EIB is critical. The breathing of dry air from the oxygen tank during underwater or 
surface swimming tends to be a stimulus for EIB. Individuals with EIB who have a low 
aerobic fitness, have a high percentage of maximal oxygen consumption (VO2 max) when 
exercising, than aerobic fit individuals [Astrand et al., 1970]. The onset and severity of 
EIB are related to exercise intensity [Carlsen et al., 2000]; hence, improved fitness 
allows asthmatics to work at a lower VO2max percentage to reduce EIB [Henriksen et al., 
1983]. It has been shown that between running (free-range and treadmill) and cycling, 
free-range running caused the most EIB [Anderson et al., 1971]. Βeta agonists could 
prevent EIB, via a direct effect on bronchial smooth muscle. In addition, the mast cell 
stabilizer such as sodium cromoglycate, which block the release of mediators from mast 
cells [Davies, 1968; Poppius et al., 1970], are useful in reducing the severity of EIB 
when taken prior to exercise [Silverman et al., 1972]. 
1.4.1.1.   Mechanism of Exercise Induced Bronchoconstriction 
Although the exact explanation for the mechanism of EIB has not been found yet, 
the crucial stimulus for EIB is heat loss or water loss from the airways during exercise. 
Factors used to determine the severity of EIB include pulmonary ventilation, water 
content of the airways and the temperature of inspired air. Deal and colleagues showed 
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a correlation between the severity of EIB and respiratory heat loss [Deal et al., 1979a]. 
Deal et al., placed emphasis on thermal load rather than the drying of the airways. Deal 
and colleagues concluded that the magnitude of EIB is directly proportional to thermal 
load on the airways. This confirms the importance of the temperature of the inspired air 
in EIB. The airway cooling and drying are considered to stimulate the release of 
inflammatory mediators such as  prostaglandins [Finnerty et al. 1990], and leukotrienes 
[Reiss et al., 1997]. Therefore, the control of the rate of water loss from the airways and 
the inspired water content is key to managing EIB. 
1.4.1.2. Refractoriness in Exercise Induced Bronchoconstriction  
 A consequence of EIB following repeated exercise challenges is refractoriness. 
The airway response decreases as the interval between exercise challenges decrease 
[Edmunds et al., 1978]. Cross refractoriness also exists between EIB and 
hyperventilation induced bronchoconstriction (HIB) [Bar-Yishay et al., 1983; Ben Dov et 
al., 1983]. Refractoriness to EIB and hyper-osmolar challenges is due to the release of 
inhibitory prostaglandins, whose effect persists for 30-60 minutes [Margolskee et al., 
1988; Mattoli et al., 1978]. Manning et al’s crossover challenges with exercise and 
leukotriene D4 (LTD4 with and without a prostaglandin synthetase inhibitor) found out 
that, refractoriness with all types of paired challenges were reduced by the 
prostaglandin inhibitor [Manning et al., 1993]. This implicates LTD4 in EIB and the 
release of inhibitory prostaglandins in refractoriness to exercise. 
1.4.1.3. Similarities between Exercise Induced Bronchoconstriction and 
Adenosine 5’ Monophosphate (AMP) 
In a study by Godfrey et al., it was found that direct challenge by methacholine 
was able to distinguish both asthma and pediatric COPD from their controls with a 
sensitivity of 82% to 92%. However, the methacholine challenge test could not 
distinguish between asthma and pediatric COPD. Interestingly, both EIB and AMP 
distinguished asthma and pediatric COPD from their controls with a sensitivity and 
specificity of 85% to 90%. What’s more, exercise and AMP were able to distinguish 
asthma from pediatric COPD with a sensitivity and specificity of 85% to 90% [Avital et 
10 
 
al., 1995; Godfrey et al., 1991]. This suggests a similarity in the mechanisms of the EIB 
and AMP. Perhaps, shared intermediate pathways that involve the release of mediators 
of inflammation exist between AMP stimulation and EIB. 
1.4.2. Eucapnic Voluntary Hyperpnea (EVH) 
Eucapnic voluntary hyperpnea (EVH) is a recommended laboratory test used in 
the identification of indirect agents of AHR such as EIB [Rundell KW et al., 2004]. The 
EVH test involves inhaling a dry gas mixture containing 4.9% to 5% carbon dioxide, 
21% oxygen, and the remaining gas as nitrogen [Anderson, 2010]. EVH protocol 
requires the participant to hyperventilate the dry gas mixture for 6 minutes at 30 times 
FEV1. The maximum level of ventilation achieved during exercise is 17-21 times the 
FEV1, which is below the ventilation achieved by voluntary hyperventilation (30 times 
the FEV1). The high ventilation rate and the dry air result in a low rate of false negative 
test results for EIB. Although a United Kingdom study of the EVH test concluded that 
EVH could help identify the EIB in previously undiagnosed elite athletes, the clinical 
diagnosis of EIB was not confirmed by the test result [Dickinson et al., 2011]. 
1.4.3. Adenosine 5’ Monophosphate  
Adenosine is a potent bronchoconstrictor that stimulates the (non-osmotic) 
release of mediators from airway mast cells [Cushley et al., 1985; Driver et al., 1991]. It 
has been shown in mast cells derived from mouse bone marrow in tissue culture that, 
adenosine potentiates the release of preformed mediators, and not the newly generated 
mediators [Marquardt et al., 1984]. Adenosine induces bronchoconstriction indirectly via 
stimulation of adenosine 2B receptors on mast cells. This results in the release of 
mediators from mast cells [Phillips et al., 1990; Peachell et al., 1988; Polosa et al., 
1995]. Results from clinical studies have shown that, bronchial hyperreactivity to AMP 
depicts allergic airway wall inflammation more accurately than bronchial hyperreactivity 
to methacholine [van Velzen et al., 1996; Oosterhoff et al., 1993].It has been 
demonstrated that, AMP correlates with sputum eosinophilia in allergic rhinitis than 
methacholine correlating with sputum eosinophilia [Polosa et al., 2000]. This supports 
the notion that AMP is a better marker for bronchial inflammation than methacholine. 
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Furthermore, AMP has been shown to be a more sensitive marker in identifying mild 
allergic airway inflammation. AMP has a positive correlation with the number of 
eosinophils in sputum and in peripheral blood. However, AMP is a less potent stimulus 
for bronchoconstriction than methacholine [Van den Berge et al., 2001]. AMP and 
methacholine responsiveness are not correlated with each other. This suggests that 
each challenge represents a different path to bronchoconstriction. 
1.4.4. Mannitol  
Mannitol is a naturally occurring sugar alcohol [Anderson et al., 1997] in fruits 
and vegetables. Mannitol causes bronchoconstriction when inhaled by some people 
with hyperresponsive airways especially some asthmatics. Mannitol is used as a 
pharmaceutical excipient, food additive, and bulk sweetener. Mannitol and exercise can 
also be used as separate tools in assessing bronchial hyperresponsiveness. Mannitol 
achieves bronchoconstriction by creating an osmotic condition via increasing the 
osmolarity of airway surface liquid. The tissue dryness or lack of moisture leads to the 
release of mediators like prostaglandins, leukotrienes, histamine from mast cells, and 
other inflammatory cells. Adverse effects of mannitol include headache, throat irritation, 
nausea, cough, rhinorrhea, dyspnea, chest discomfort, and wheezing in those with a 
positive test. Mannitol challenge tests are generally safe and well tolerated [Brannan et 
al., 2005]. 
1.4.4.1. Mannitol Challenge testing 
The mannitol challenge was performed using a mannitol test kit named Aridol 
(Aridol; Pharmaxis Inc. French’s Forest New South Wales, Australia). The mannitol kit 
consists of mannitol capsules and an inhaler device. The mannitol dry powder challenge 
involves the inhalation of increasing doses of mannitol dry powder up to a cumulative 
dose of 635 mg. FEV1 is measured one minute after each dose of mannitol [Brannan et 
al., 2005; Anderson et al., 2009]. A 15% fall in FEV1 from the baseline FEV1 is 
considered a positive response to mannitol. Mannitol can indicate the presence of EIB 
in an individual. A positive response to mannitol is more likely in atopic patients; 
however, a positive response has also been recorded in non-atopic patients. The 
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provocative dose of mannitol causing the 15% fall in FEV1 is termed PD15. The PD15 
serves as an index to assess an individual’s sensitivity to mannitol. The response dose 
ratio (RDR) is another index used in expressing reactivity or rate of change of airway 
response to mannitol. The RDR is calculated by dividing the change in FEV1 by the 
dose of mannitol that provoked the fall in FEV1 [Brannan et al., 2005]. Both the PD15 
and RDR values have been shown to be indirect indices of the severity of EIB [Kersten 
et al., 2009]. Alternatively, some investigators use a 10% decrease in FEV1 of the 
patient’s response to mannitol in comparison to the patient’s response to EVH and 
exercise [Holzer et al., 2003]. 
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2. LITERATURE REVIEW 
2.1. Allergen-induced increase in mediator release, airway inflammation and 
eosinophils 
Atopic IgE mediated airway response to inhaled allergens induces the early 
asthmatic response, late asthmatic response, an increase in AHR, eosinophilia, and 
airway inflammation. The airway response to allergen challenge results in an increase in 
mediators of bronchoconstriction; hence, a subsequent direct or indirect challenge will 
lead to a more airway response than a direct or indirect challenge alone. It has been 
identified that there is an increase in bronchoalveolar eosinophils after allergen 
challenge. This increase occurs in participants with a dual asthmatic response (DAR) 
namely, the early and the late asthmatic response [de Monchy et al., 1985]. The 
increase in airway responsiveness and eosinophils following allergen challenges are 
known to be inhibited by corticosteroids. This suggests that the airway inflammation 
seems to be the cause of LAR and increased airway hyperresponsiveness (AHR) 
[Cockcroft et al., 1993]. The EAR is associated with the release of mediators of 
bronchoconstriction such as histamine [Keyzer et al., 1984], leukotrienes [Manning et 
al., 1990], and prostaglandins [Shephard et al., 1985].  
2.2. Allergen-induced increase in airway response to direct challenges: 
Methacholine and histamine challenges 
Increase in non-allergic AHR is another feature of asthma. The degree of AHR 
has been shown to be a significant determinant in the airway response to allergen 
[Killian et al., 1976]. This supports an earlier observation that, natural grass pollen 
exposure increases bronchial reactivity to inhaled histamine in grass pollen-allergic 
asthmatics [Altounyan 1964; Howell, 1977]. Cockcroft et al., reported an increase in the 
airway response to both histamine and methacholine 7 hours and several days following 
allergen exposure [Cockcroft et al., 1977]. Cockcroft et al., measured non-allergic 
bronchial reactivity to inhaled histamine and methacholine, before and after allergen 
inhalation in thirteen participants. Although the allergen inhalation produced EAR (19%-
40%), some of the participants also experienced an LAR. What’s more, the non–allergic 
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bronchial reactivity persisted for up to seven days after allergen inhalation. Changes in 
bronchial reactivity to inhaled histamine and methacholine were examined eight hours 
after allergen inhalation. The PC20 for inhaled histamine was significantly reduced in 
seven participants, with the reduction reaching a maximum between eight and fifty-six 
hours post allergen inhalation . Similarly, the PC20 for methacholine was also reduced 
significantly in six participants with a maximum between eight and thirty-two hours. 
Although the increase in reactivity to histamine was greater than that of methacholine, 
the difference was not significant. It is worth mentioning that, the reduction in histamine 
and methacholine PC20 only happens in the LAR participants. LAR participants are 
participants with asthma that have 10% to 15% drop in FEV1 between 3 and 5 hours 
after allergen exposure. This drop in FEV1 follows an earlier drop 10 minutes and 
recovery after the participant is in contact with the allergen that he/she is susceptible to. 
It has been shown that the allergen-induced increase in bronchial reactivity to 
methacholine can be abrogated by corticosteroids [Lötvall et al., 2011]. 
2.3. Allergen-induced increase in airway response to indirect challenges 
(Exercise Induced Bronchoconstriction) 
It has been well documented that LAR appears at three to ten hours following 
allergen exposure in some atopic asthmatics [Cartier   et al., 1982]. It has also been 
documented that LAR can appear following strenuous exercise [Bierman et al., 1984; 
Speelberg et al., 1991]. However, the prevalence of exercise-induced LAR is lower than 
allergen-induced LAR [Bierman et al., 1984; Lee et al., 1989], even though a similar 
pattern has been observed due to the release of similar mediators [Lee et al., 1983]. 
Young et al., have observed the occurrence of an LAR to exercise following allergen 
challenge [Young et al., 1998]. However, one cannot distinguish between the allergen-
induced LAR and the exercise-induced LAR. Although there are controversies 
surrounding the existence of exercise induced LAR, it has also been reported that there 
is an effect of exercise-induced LAR on allergen-Induced LAR. Koh et al. reported an 
increase in airway responsiveness to allergen twenty-four hours after exercise 
challenge [Koh et al., 1994]. LAR to exercise may also occur in adult asthmatics 
following allergic LAR [Boulet et al., 1992]. A key feature of LAR is inflammation; as 
15 
 
such, one can infer that, the influx of inflammatory cells, and hence the increase in 
mediators of inflammation culminates into the enhancement of bronchial 
responsiveness [Durham, 1991]. 
2.4. Allergen induced increase in the airway response to indirect challenges: 
Adenosine 5’ Monophosphate 
AMP is an indirect stimulus that provokes bronchoconstriction via mast cell 
degranulation and the release of pro-inflammatory mediators [Polosa et al., 1995]. Mast 
cells are prominent sources of mediators of inflammation in atopic asthma; as such, a 
bronchial response to AMP can be deemed as a more direct marker of allergic 
inflammation, than when compared to direct challenges [Van den Berge et al., 2001; 
Prieto et al., 2002a]. There have been indications that in sensitized participants with 
atopic asthma or rhinitis, natural exposure to seasonal pollen elicits an increase in 
airway response to AMP [Prieto et al., 2002b]. In a study by Lopez et al., it was shown 
that AMP PC20 values were significantly lower in participants with pollen allergy during 
the pollen season. These participants included both healthy and patients with seasonal 
allergic rhinitis with or without mild asthma [Lopez et al., 2012]. The decrease in AMP 
PC20 is consistent with increased airway sensitivity to AMP following exposure to pollen. 
This suggests that airway sensitivity to indirect bronchoconstrictors like AMP may be 
increased due to the presence of pro inflammatory stimuli, stemming from the allergen 
exposure. 
 
2.5 Summary 
 
Asthma is a heterogeneous airway phenomena characterized by spontaneous 
reversible airflow obstruction or with treatment. The two main features of asthma are 
chronic airway inflammation and airway hyperresponsiveness. These two features 
represent key symptoms that influence the choice of treatment for asthma. The 
diagnosis of asthma can be deduced from assessing airway functioning. Airway 
assessment can be achieved through bronchoprovocation challenges using stimuli such 
as methacholine, mannitol, exercise, cold air, histamine, hypertonic solution, and AMP. 
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The stimuli are classified into direct (methacholine and histamine) and indirect 
(mannitol, exercise, cold air, AMP and hypertonic solution) based on their site of action 
on the airways. 
Allergen is a common trigger for asthma as such allergen inhalation is a very 
useful clinical and research tool for evaluating asthma. Allergen inhalation leads to 
crosslinking of allergen –specific IgE bound to IgE receptors on mast cells and 
basophils. This leads to release of mediators of bronchoconstriction. The timeframe of 
bronchoconstriction happening within three hours is termed early asthmatic response. A 
subsequent bronchoconstriction occurring between 3 and 8 hours is termed late 
asthmatic response.  
It has been shown that asthmatics exposed to allergen have a different response 
to methacholine challenge than they did before allergen exposure. Our mandate is to 
investigate if this change in response happens with mannitol. 
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Figure 2.1. Overview of allergen, direct stimuli and indirect stimuli pathway to bronchoconstriction 
  
 
 
 
 3. ALLERGEN-INDUCED CHANGES IN AIRWAY RESPONSE TO METHACHOLINE 
AND MANNITOL THREE AND TWENTY FOUR HOURS AFTER ALLERGEN 
CHALLENGE 
3.1. Rationale 
It has been shown that the PC20 for AMP (indirect challenge stimulus similar to 
mannitol), correlates better with sputum eosinophilia (a measure airway inflammation) 
than methacholine PC20. Although the increase in airway hyperresponsiveness after 
allergen challenge can be seen and measured at seven and twenty-four hours; it has 
been shown in as early as three hours. Although it has also been shown that there is an 
increased responsiveness to methacholine after allergen challenge, we do not know the 
responsiveness to mannitol after allergen challenge. However, we do know the 
presence of refractoriness of the airways to mannitol in repeated mannitol challenges 
and cross-refractoriness within the indirect stimuli causing bronchoconstriction. The 
occurrence of refractoriness causing a decrease in airway response to mannitol three 
hours post allergen challenge, calls for an extension of the post allergen’s time point 
from three to twenty-four hours in a second study. 
3.2. Background 
Airway responsiveness to direct bronchoconstrictors such as methacholine has 
been shown to increase following allergen challenge, and has been observed primarily 
in those with a late asthmatic response. Indirect airway challenges, which include both 
an allergen challenge and a mannitol challenge, are expected to have a greater positive 
response than when an allergen challenge is done with a direct challenge like 
methacholine. Contrary to our expectations, the three-hour post allergen challenges 
resulted in a decreased airway response to mannitol; hence, a 24-hour post allergen 
challenge was aimed at ruling out refractoriness. Although FENO measurements were 
taken in the three-hour study, they were taken at the beginning of each visit to track 
inflammation at the start of the visits in the three-hour study. In addition to FENO 
measurements taken at the beginning of each visit in the twenty-four hour study, FENO 
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 measurements were also made at the seven and twenty-four hour  after allergen 
challenge to track airway inflammation. 
3.3. Hypothesis 
Since the PC20 for AMP correlates better with airway inflammation than 
methacholine PC20, we expect changes in airway responsiveness measured both at 
three and twenty-four hours post allergen challenge, to be greater when tested with 
mannitol than methacholine. 
3.4. Objectives 
Among the objectives we were examining in the study were as follows: 
• The change in airway responsiveness at three and twenty-four hours after allergen 
challenge measured with mannitol.  
• The change in airway responsiveness at three and twenty-four hours after allergen 
challenge measured with methacholine. 
3.5. Study Design  
The study was first designed to study the behavior of methacholine and mannitol 
challenges three hours after allergen challenge. However, the results from the three-
hour study contradicted the hypothesis we proposed. We repeated the study but 
allowed twenty-four hours after allergen challenge before looking at the behavior of 
methacholine and mannitol. In the twenty-four hour study a slight change was made in 
taking FENO measurements as compared to the three-hour study 
Both studies were  phase III, single center, and open-label randomized studies. A 
screening methacholine challenge and an allergen skin test were run on the first visit. 
However, the screening methacholine challenge and the allergen skin test were not 
tested in individuals who had already successfully completed the three-hour study and 
were participating in the twenty-four-hour post allergen challenge. After the participant 
had passed all the screening tests, the participant was asked to come in twenty-four 
hours later for a FENO reading, and either a methacholine or mannitol challenge. After  
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 24 hours, the participant was asked to come again for an additional FENO reading and 
an allergen challenge. 
In the case of the three-hour study, the participant underwent another methacholine or 
mannitol challenge 3 hours after the allergen challenge, based on the challenge the 
participant did 24 hours earlier. If the participant did a methacholine challenge 24 hours 
earlier, the participant will repeat the methacholine challenge three hours after the 
allergen challenge. If the participant did a mannitol challenge 24 hours earlier, the 
participant will repeat the mannitol challenge three hours after the allergen challenge. 
Two weeks later, the methacholine challenge is replaced with the mannitol challenge or 
the mannitol challenge is replaced with the methacholine challenge. In both cases, the 
allergen challenge stays the same. If the first two visits were methacholine on visit-2 
and allergen-methacholine on visit-3,then the next two visits were mannitol on visit-4 
and allergen mannitol on visit-5 and vice versa. The schedule of assessment for the 
three-hour post allergen study is shown below. 
Table 3.1. Schedule of assessments for the three-hour study. 
 
 
In the 24-hour post allergen challenge, twenty-four hours following the start of the 
allergen challenge, the participant was required to perform another FENO test and 
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Allergen skin 
test. 
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 undergo another methacholine or mannitol challenge. If the participant did a 
methacholine challenge 24 hours earlier, the participant will repeat the methacholine 
challenge 24 hours after the allergen challenge. If the participant did a mannitol 
challenge 24 hours earlier, the participant will repeat the mannitol challenge 24 hours 
after the allergen challenge. After at least two weeks, the methacholine challenge was 
replaced with the mannitol challenge or the mannitol challenge was replaced with the 
methacholine challenge. In both cases, the allergen challenge stays the same. If the 
first three visits were methacholine on visit-2, allergen on visit-3 and methacholine on 
visit-4, then the next three visits were mannitol on visit-5, allergen on visit-6 and 
mannitol on visit-7. If the first three visits were mannitol on visit-2, allergen on visit-3 and 
mannitol on visit-4, then the next three visits were methacholine on visit-5, allergen on 
visit-6 and methacholine on visit-7. The second, third and fourth visits were separated 
from the fifth, sixth and seventh visits by at least a two week washout period.   
 
Table 3.2. Schedule of assessments 24-hour post allergen study 
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 The order of the challenges that is methacholine/allergen /methacholine and 
mannitol/allergen/ mannitol) were randomized but not concealed. The study took place 
from September 2012 until the end of March 2014. The drugs used in the study included 
methacholine–powder for solution, and mannitol. The methacholine used for inhalation 
has been approved for testing in bronchoprovocation testing. The mannitol-capsules 
were punctured and inhaled by the inhaling device (osmohaler) in the mannitol kit. 
Mannitol is also a natural health product approved for use in bronchoprovocation testing 
in a number of countries, including Australia and the USA, but not yet in Canada 
3.5.1. Primary Endpoints. 
• Difference in PD15 of mannitol before allergen challenge and three hours after 
allergen challenge (∆log PD15).  
• Difference in the dose response ratio (DRR) of mannitol before allergen challenge 
and twenty-four hours after allergen challenge ).  
• Difference in PC20 of methacholine before allergen challenge and three hours after 
allergen challenge (∆log PC20). 
• Difference in PC20 of methacholine before allergen challenge and twenty-four hours 
after allergen challenge (∆log PC20). 
3.5.2.   Statistical Analysis. 
Statistical analysis was performed with Microsoft Excel 2013 for Windows (Part 
of Microsoft Office Professional Plus 2013, Redmond WA, USA), Statistix (version 10 
for Windows Tallahassee, Florida, USA), and Sigma plot (version 12.5 for Windows San 
Jose, California, USA).  We compared bronchoprovocation data using a paired t-test. 
The level of significance was set at 0.05. Both studies were appropriately powered 
(99%) to detect a full concentration change in methacholine PC20. 
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 3.6.   Methods. 
3.6.1.   Participants. 
Ten atopic asthmatic participants aged 18-65 previously known to researchers or 
recruited from the University of Saskatchewan general population completed the three-
hour post allergen study. Eleven participants also from the above group completed the 
twenty-four-hour post allergen study. The participants were provided with a University of 
Saskatchewan Biomedical Research Ethics Board approved consent form prior to 
participation in the study. Participants who participated in the three-hour post allergen 
study project were allowed and actively recruited into this project. These participants 
were not required to undergo screening methacholine and skin prick testing for 
allergies.  
 
3.6.2.   Exclusion criteria.  
Participants were excluded from the study based on the following: 
• The screening methacholine challenge resulted in a methacholine PC20 greater 
than 16mg/ml. Methacholine challenge is positive when there is a fall of about 
20% in FEV1 after administering about 32 mg/ml of methacholine. Hence more 
than 16mg/ml of methacholine without an FEV1 of 20% will be considered as a 
negative methacholine challenge. 
• Baseline FEV1 of less than 70% predicted.  A participant with baseline of less 
than 70% is not an advisable candidate for bronchoprovocation challenges 
especially challenges involving allergen could potentiate a fall in FEV1 leading to 
breathing problems which could be fatal if not monitored properly. 
• There were no clinically relevant positive allergies indicated with the allergen skin 
test. Allergen challenges can only be done in participants with a susceptibility to 
an allergen in the lab hence a positive allergen test is required. 
In addition, participants could not have any requirement for controller medications such 
as inhaled glucocorticosteroids such as budesonide and fluticasone (alone or in 
24 
 
 combination with long acting beta agonists). Participants should not have had any 
significant medical comorbidity, or any respiratory infection or allergen exposure within 
the 4 weeks of the study start date. Pregnant or lactating female participants were also 
excluded from the study. A participant was also excluded from the study if he or she 
was unable to stay off bronchodilators for an appropriate length of time. 
3.6.3.   Methacholine Challenge. 
The procedures for each methacholine challenge were undertaken in accordance 
with the ATS guidelines from 1999 [Crapo et al., 2000]. 
1. Methacholine was prepared at the following concentrations (mg/ml): 0.03, 0.06, 
0.125, 0.25, 0.50, 1.00, 2.00, 4.00, 8.00, and 16.00.   
2. Baseline spirometry was performed with a primary focus on FEV1 and FVC 
(actual and predicted values). 
3. By means of a Bennett-Twin jet nebulizer (calibrated to an output of 0.13 ml/min), 
via a face mask and with a nose clip on, the first concentration (diluent – normal 
saline) was administered for a period of 2 minutes during which the participant 
was asked to breathe normally. 
4. The FEV1 was measured at 30 and 90 seconds after the nebulization had ended.  
5. The FEV1 values were recorded and the lowest FEV1 post methacholine 
inhalation compared to the lowest FEV1 post diluent inhalation was assessed.  A 
fall in FEV1 of 20% was required. 
6. Until the target FEV1 was achieved, or a maximum concentration of 
methacholine was reached, steps 3 through step 5 were repeated for each 
concentration administered. 
7. Participants were provided with bronchodilator (salbutamol) to reverse induced 
bronchoconstriction if necessary. 
The methacholine PC20 was then calculated for each participant using the formula 
below. 
Methacholine PC20  = antilog [log C1 + ((log C2- log C1)(20-R1)/(R2-R1)]…..……... 
(3.1) 
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 Where,  
C1= second to last methacholine concentration. 
C2= final concentration of methacholine resulting in ≥ 20% drop in FEV1. 
R1= percentage drop in FEV1 after C1. 
R2= percentage drop in FEV1 after C2. 
In the event where the participant’s fall in FEV1 was ≥ 17%, a single point extrapolation 
formula was used to theoretically obtain the methacholine PC20 [Jokic et al., 1998]. This 
formula is as follows.  
Methacholine PC20 = [20/(current % fall in FEV1)] * last concentration of methacholine 
…………………………………………………………………………………………….... (3.2) 
 3.6.4.   Mannitol Challenge. 
  A standardized mannitol challenge protocol has been developed [Anderson et 
al., 1997] and mannitol was supplied by the manufacturer. Spirometry was performed 
before the challenge and the reproducibility of the resting baseline FEV1 was 
established. The participant was seated comfortably and encouraged to maintain good 
posture to assist the effective delivery of mannitol to the lungs. The test was conducted 
as follows.  
1. The participant was directed to breathe through the mouth with the help of an 
applied nose clip. 
2. The 0 mg capsule was inserted into the inhalation device and was punctured 
by pressing buttons on the sides of the device once slowly.  
3. The participant was asked to exhale completely before inhaling from the 
device using a controlled and rapid deep inhalation. 
4. At the end of the deep inhalation, a 60-second timer was started with the 
participant holding his or her breath for 5 seconds before exhalation through 
the mouth.   
5. After the 60 seconds had elapsed, the FEV1 was measured in duplicate 
6. Steps 2 through 5 were repeated following the dose steps in the table below 
until the patient had a positive response, or the total cumulative dose of 635 
mg of mannitol had been administered. 
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 7. Participants were provided with bronchodilator (salbutamol) to reverse 
induced bronchoconstriction if necessary. 
 
Table 3.3. Dosage of the capsules of mannitol for the mannitol challenge. 
Dose # Dose (mg) Cumulative Dose (mg) Capsule / Dose (mg) 
1  0 0 1x 0 mg 
2 5 5 1x5mg 
3 10 15 1x10mg 
4 20 35 1x20mg 
5 40 75 1x40mg 
6 80 155 2x40mg 
7 160 315 4x40mg 
8 160 475 4x40mg 
9 160 635 4x40mg 
 
 A positive response was achieved when the participant experienced a 15% fall in FEV1 
compared with the 0 mg dose. A mannitol PD15 was calculated for each participant 
twenty-four hours before and three hours after the allergen challenge using the formula 
below in the three-hour study.  
mannitol PD15 = antilog [log D1+ (log D2-log D1)(15-R1)/(R2-R1)]…………………(3.3) 
 
Where,  
D1= second to last cumulative mannitol dose. 
D2= final cumulative dose of mannitol resulting in a ≥ 15% drop in FEV1. 
R1= percentage drop in FEV1 after D1. 
R2= percentage drop in FEV1 after D2. 
In the event where the fall in FEV1 was not quite 15% (e.g. 10-14%), a single point 
extrapolation was used to theoretically obtain the mannitol PD15. This formula is as 
follows. 
mannitol PD15 = [15/ % fall in FEV1] cumulative dose of mannitol…………………… (3.4) 
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  In  the twenty-four hour study, mannitol responsiveness was assessed using a 
dose response ratio. The dose response ratio was calculated by dividing the cumulative 
dose of mannitol in mg by the percentage fall in FEV1 at that dose. 
3.6.5.   Allergen Challenge. 
The selected allergen was administered using a Wright nebulizer and two 
minutes of tidal breathing. The first concentration given ranged from three or four 
doubling concentrations below the predicted allergen PC20. FEV1 was measured ten 
minutes after each concentration of allergen was given until the targeted fall of 20% or 
more from the baseline was reached. In the three-hour post allergen study, lung 
function was monitored in the asthma lab at various time points over the next 3 hours 
after the allergen challenge. In the twenty-four hour post allergen study, lung function 
was monitored in the asthma lab at various time points over the next 7 hours after the 
allergen challenge. The allergen challenge was performed as follows:  
1. Baseline spirometry was performed to determine the highest FEV1 for 
comparison with the FEV1 post allergen inhalation to determine the percent fall in 
FEV1. 
2. A target fall in FEV1 was calculated at 80% of the participants’ baseline FEV1. 
3. By means of a Wright nebulizer (calibrated to an output of 0.13 ml/min), and with 
the use of a nose clip, the first concentration of allergen was administered for a 
period of exactly two minutes. The first concentration was three or four 
concentrations below the predicted allergen PC20. Participants were asked to 
breathe normally via a mouthpiece.  
4. An FEV1 was measured at ten minutes after the nebulization had ended. If the 
target fall in FEV1 was not reached, the next concentration of allergen was 
administered. 
After the FEV1 had fallen by 20% or more, allergen administration was halted and the 
FEV1 was measured at each of the following time points: 20, 30, 45, 60, 90,120, and 
180 minutes in the three-hour post allergen study. FEV1 was measured at 20, 30, 45, 
60, 90, 120, 180, 240, 300, 360, and 420 minutes in the twenty-four-hour post allergen 
study. Spirometric measurements were used to assess the development (or not) of the   
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 late asthmatic response. Inhaled glucocorticosteroid (fluticasone propionate) was 
administered to some participants who underwent either methacholine or mannitol 
challenges three hours after allergen challenge. 
3.6.6.   Skin Prick Test and Skin Test Endpoint.  
 Each individual was skin-tested to determine and confirm his or her sensitivity to 
common aeroallergens. This involved the introduction of droplets of different allergens 
on the forearm, and pricking within the allergenic solutions to introduce the allergen to 
just below the skin. Introduction of the allergen elicited an allergic reaction in the form of 
a bright reddish bump on the forearm. An appropriate allergen was chosen based on 
the response to the skin prick test and clinical history. Doubling dilutions (1:8 to 1:1024 
or higher as necessary) of the chosen allergen were prepared and used to perform the 
skin test endpoint. The skin test endpoint was administered by introducing different 
concentrations of the sensitized droplets to the forearm. Pricks were made in the 
droplets of different concentrations to introduce the allergen to just below the skin. The 
skin test endpoint was defined as the minimum dilution of the allergen that produced a 
2mm wheal in diameter or smaller. This was used in conjunction with the results of the 
screening methacholine challenge to determine the predicted allergen PC20 for the 
allergen inhalation challenge using the formula below [Cockcroft et al., 1987; Cockcroft 
et al., 2005].  
 
Predicted allergen PC20 = antilog [0.68 * log (methacholinePC20 * skin test 
endpoint)]…………………………….. ………………………..…………………….. (3.5) 
3.6.7.   Fractional Exhaled Nitric Oxide Measurements (FENO). 
FENO is a non-invasive tool used in assessing airway inflammation in allergic diseases 
like asthma. It is believed that during allergic airway inflammation there is an increase in 
eosinophil recruitment and an increase in nitric oxide in the airways.  
 FENO was measured using a chemiluminescence gas analyzer (Niox, Aerocrine 
Inc., New York, NY). Participants performed an inhalation to total lung capacity. This 
was followed by an exhalation with a constant flow rate of 50mL/sec via a 
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 filter/mouthpiece. The procedure was performed in triplicate and continued until at least 
two measurements were reproducible within 10%. FENO measurements were 
performed before methacholine challenges, mannitol challenges, and pre allergen 
challenges in the three-hour post allergen challenge. In the twenty-four hour post 
allergen challenge, FENO measurements were performed before all methacholine, 
mannitol and allergen challenges. Additional measurements were made at 7 hours and 
24 hours post allergen challenge.  
For the three-hour study, the participants read and signed the consent form 
before they were allowed into the study. Screening for the study included testing 
negative for pregnancy in females. All participants in the study are required to pass a 
methacholine challenge and have an allergic reaction to at least one of the allergens in 
the lab. FENO measurement is done at the start of each visit after the subject has 
passed all screening requirements. On the second visit the participant underwent either 
methacholine or mannitol challenge  In addition the allergen is titrated to figure out the 
concentration of allergen to cause a 20% fall in FEV1 from the allergen skin test.  The 
allergen challenge and methacholine or mannitol challenge is done on the next visit.  A 
two-week washout period is allowed to prevent the effects of the previous allergen 
challenge from affecting the second allergen challenge. If the visit two challenge was 
methacholine, the fourth challenge is switched to mannitol or vice versa. 
3.7. Results for three hour study  
3.7.1.   Participants. 
 Thirteen participants consented to take part in the study; however, ten atopic 
asthmatics aged between 21 and 36 completed testing successfully without any incidence 
of adverse effects. Three participants did not meet the entry criteria. The participants had 
a clinical diagnosis of mild a topic asthma at some point in their lives. Participants were 
asked to refrain from corticosteroids about four weeks before the start of the study and 
refrain from short acting bronchodilators 6 hours prior to each visit. The mean age was 
26 years ± 5.7 S.D. The mean height and weight of the participants was 171 cm ± 11.2 
S.D. and 69 kg ± 17.8 S.D. respectively. The mean baseline FEV1 was 3.46L ± 0.65 S.D.  
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 The participants had a positive methacholine challenge and had an allergic response to 
some of the allergens such as cat, horse, and house dust mite dermatophagoides 
pteronyssinus (DP). Table 3.4 below shows the participant’s demographics for the 3-hour 
post allergen challenges. 
3.7.2.   Methacholine challenge 
   The geometric mean methacholine PC20 before allergen challenge was 0.88 
mg/ml ± 0.10 S.E. The geometric mean methacholine PC20 after allergen challenge was 
0.50 mg/ml ± 0.10 S.E. The decrease in MCh PC20 was significant (p = 0.02). Table 3.5 
shows the raw data for the methacholine challenge. In addition, Figure 3.1 shows the 
various participants’ methacholine PC20 before and after allergen challenge. 
 
3.7.3.  Mannitol challenge 
The geometric mean mannitol PD15 before allergen challenge was 174mg ± 0.16 
S.E. The geometric mean mannitol PD15 after allergen challenge was 284mg ± 0.18 S.E. 
There was a significant increase in mannitol PD15 after allergen challenge (p=0.02). Table 
3.5 shows the raw data for the mannitol challenge. In addition, Figure 3.2 shows the 
individual mannitol PD15 before and after allergen challenge. 
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Table 3.4. The demographics of participants in the three-hour study.  
Participant Sex Age  
(years) 
Baseline 
FEV1 (L) 
Baseline 
FEV1 
(%predicted) 
Height 
(cm) 
Weight 
(kilogra
ms) 
Allergen information 
Allergen Skin test 
end point 
Final  
Concentration 
Inhaled 
1 F 22 3.41 100 165 68 *HDM-
DP 
1:4096 1:256 
2 M 36 3.69 86 178 82 Cat 1:4096 1:32 
3 F 21 3.16 85 173 73 Cat 1:1024 1:64 
4 F 21 3.52 96 173 66 Cat 1:512 1:16 
5 M 25 3.99 83 183 103 Cat 1:1024 1:16 
6 F 26 3.00 89 165 45 HDM-
DP 
1:128 1:1024 
7 F 24 3.06 102 155 54 Horse 1:2048 1:32 
8 F 36 2.69 93 157 53 HDM-
DP 
1:512 1:256 
9 F 21 3.10 89 168 57 Cat 1:256 1:32 
10 M 27 4.96 97 191 86 Cat 1:256 1:2 
Mean ± SD  26 ± 5.7 3.46 ± 0.65 92 ± 6.6 171 ± 
11.2 
69 ± 
17.8 
   
 * House dust mite dermatophagoides pteronyssinus 
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Table 3.5. The raw and logged PC20 and PD15 data for Methacholine and Mannitol challenges in the three-hour 
study. 
 PC20(mg/ml) PD15(mg) Log PC20 Log PD15 
Participant 
Methacholine 
Pre 
Allergen 
Methacholine 
Post 
Allergen 
Mannitol 
Pre 
Allergen 
Mannitol 
Post 
Allergen 
Methacholine 
Pre 
Allergen 
Methacholine 
Post 
Allergen 
Mannitol 
Pre 
Allergen 
Mannitol 
Post 
Allergen 
1 1.80 0.25 168 206 0.2553 -0.6021 2.2253 2.3139 
2 0.70 0.36 755 1905 -0.1549 -0.4437 2.8779 3.2799 
3 0.72 0.70 145 196 -0.1427 -0.1549 2.1614 2.2923 
4 0.94 0.36 202 275 -0.0269 -0.4437 2.3054 2.4393 
5 0.53 0.45 130 194 -0.2757 -0.3468 2.1139 2.2878 
6 0.91 0.59 28 75 -0.0410 -0.2292 1.4472 1.8751 
7 1.51 1.44 1047 2646 0.1790 0.1584 3.0199 3.4226 
8 0.27 0.28 128 78 -0.5686 -0.5528 2.1072 1.8921 
9 0.54 0.25 82 189 -0.2676 -0.6021 1.9138 2.2765 
10 3.10 1.60 N N 0.4914 0.2041 N N 
Geometric mean±SE 0.88±0.10 0.50±0.10 174±0.16 284±0.18 
N - Negative test for mannitol 
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Figure 3.1. Graph of methacholine PC20 before and after allergen challenge in the 
three-hour study. The vertical axis is a log scale. Individual data points are 
geometric means ± S.E. 
 
n = 10, p = 0.02 
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Figure 3. 2. Graph of mannitol PD15 before and after allergen challenge in the three-
hour study. The vertical axis is a log scale.  Individual data points are geometric 
means ± S.E. 
n = 9, p = 0.02 
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 3.7.4.   Baseline FENO 
The difference between pre and post allergen FENO was not significant during 
methacholine (p = 0.85) or mannitol (p = 0.42) challenges. Table 3.6 shows all FENO 
data. 
 
Table 3.6. The baseline FENO of all participants in the three-hour study 
 Baseline FENO (ppb) Log baseline FENO 
Participant 
Methacholine 
Arm 
Mannitol 
Arm 
Methacholine 
Arm 
Mannitol 
Arm 
Day1 *Day2  Day1 Day 2 Day 1 Day 2 Day 1 Day 2 
1 41 40 23 21 1.61 1.60 1.36 1.32 
2 57 150 25 25 1.76 2.18 1.40 1.40 
3 57 48 56 61 1.76 1. 68 1.75 1.79 
4 82 61 99 76 1.91 1.79 2.00 1.88 
5 92 91 79 87 1.96 1.96 1.90 1.94 
6 21 19 26 26 1.32 1.28 1.41 1.41 
7 39 38 35 40 1.59 1.58 1.54 1.60 
8 61 58 68 98 1.79 1.76 1.83 1.99 
9 39 38 35 40 1.59 1.58 1.54 1.60 
10 111 105 50 49 2.05 2.02 1.70 1.69 
Geometric mean ± SE 54±1.2 55±1.2 44±1.2 46±1.2 
*Day 2 measurements were taken before the allergen challenge 
 
 
3.7.5.   Baseline FEV1. 
There were no significant differences between baseline FEV1 values for either the 
methacholine arm or the mannitol arm (p=0.42 and p=0.42). Raw data are shown in Table 
3.7 below.   
 
 
 
 
. 
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 Table 3.7.  The baseline FEV1 of participants in the three-hour study. 
 Baseline FEV1 (L) 
Participant  
Methacholine Arm Mannitol Arm 
Pre Post Pre Post 
1 3.39 3.33 3.31 3.25 
2 3.53 3.73 3.73 3.54 
3 2.99 3.04 2.75 2.91 
4 4.41 3.33 3.48 3.24 
5 3.31 3.51 3.75 3.42 
6 2.84 2.77 2.78 2.66 
7 2.99 3.05 3.02 3.00 
8 2.77 2.48 2.43 2.43 
9 3.10 3.05 2.86 3.10 
10 4.72 4.77 4.87 4.95 
mean±SE 3.41±0.21 3.31±0.20 3.30±0.22 3.25±0.22 
3.7.6.   Allergen Challenge 
There was no significant difference between the two allergen challenges. Results 
from the allergen challenges were grouped into methacholine arm in table 3.8 and 
mannitol arm in table 3.9. Figure 3.3 shows the similarities between the allergen 
challenges on the mannitol and methacholine arm. 
Table 3.8.  Percentage FEV1  fall following allergen challenge in the methacholine 
arm in the three-hour study. 
 
Participants 
%∆FEV1 
@ 10m 
%∆FEV1 
@ 20m 
%∆FEV1 
@ 30m 
%∆FEV1 
@ 45m 
%∆FEV1 
@ 60m 
%∆FEV1 
@ 90m 
%∆FEV1 
@ 120m 
  1 55.2 51.7 48.3 42.9 21.9 14.7 7.2 
2 16.4 18.2 17.2 13.1 8.6 4.8 4.8 
3 19.7 13.8 19.4 8.6 7.2 0.1 5.6 
4 20.4 19.2 15.3 8.7 7.5 1.2 0.9 
5 27.1 14.5 22.2 8.5 6.6 0.5 2.6 
6 19.1 15.9 26.4 23.1 20.2 16.6 5.1 
7 15.7 29.2 20.7 9.8 14.1 1.0 0.0 
8 29.0 25.0 22.6 16.1 11.3 12.5 4.8 
9 35.7 30.8 19.3 21.3 20.0 17.4 3.0 
10 37.7 35.0 34.8 29.8 18.7 14.3 8.6 
mean±SE 27.6±3.9 25.3±3.7 24.6±3.1 18.2±3.6 13.6±1.9 8.31±2.3 4.26±0.8 
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Table 3.9 Percentage FEV1 fall following allergen challenge in the mannitol arm in 
the three-hour study.. 
Participant 
%∆FEV1 
@10m 
%∆FEV1 
@20m 
%∆FEV1 
@30m 
%∆FEV1 
@45m 
%∆FEV1 
@60m 
%∆FEV1 
@90m 
%∆FEV1 
@120m 
1 44.3 17.8 11.7 4.0 5.6 0.3 0.3 
2 22.6 38.1 35.6 26.8 19.5 0.8 5.9 
3 16.8 24.1 18.6 17.9 16.2 3.9 0.0 
4 23.8 24.1 21.3 12.3 7.7 3.7 0.1 
5 19.6 26.0 15.5 10.8 6.4 2.0 1.0 
6 19.5 21.1 21.8 16.9 7.1 7.9 0.8 
7 22.7 27.7 11.3 7.3 4.0 2.3 4.0 
8 26.7 23.9 24.7 17.7 17.7 15.6 6.7 
9 21.6 20.0 18.4 15.8 12.9 5.2 2.9 
10 21.8 21.6 19.6 12.7 11.3 3.6 5.7 
mean+SE 23.9±2.4 24.4±1.8 19.9±2.2 14.2±2.0 10.8±1.7 4.5±1.4 2.7±0.8 
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Figure 3.3. Mean changes in FEV1 following allergen challenge in the methacholine 
and mannitol arm in the three-hour study 
3.8.   Discussion for three-hour study. 
Airway responsiveness to methacholine has been shown to increase following allergen 
challenge. However, we do not know airway responsiveness to mannitol following 
allergen challenge.  We have shown in the 3-hour study that the airway responsiveness 
to methacholine was increased by almost one doubling concentration. Conversely, 
airway responsiveness to mannitol was reduced. The change in airway responsiveness 
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 to methacholine was expected. This confirms the observation by Cockcroft et al., that 
allergen-induced challenge produces an increase in airway responsiveness to direct 
stimuli  [Cockcroft et al., 1987a; Amakye et al., 2013]. Subsequent studies attributed the 
increase in airway response and inflammation to LAR following allergen challenge 
[Gauvreau et al., 1996]. The time frame however, in which participants experience 
increased airway responsiveness to methacholine following allergen challenge has 
been documented as early as 3 hours [Durham et al.,1988]. Although allergen-induced 
airway eosinophilia and allergen-induced airway responsiveness seem to occur at 
similar time points, they are not associated through a cause and effect relationship 
[Leckie et al., 2000].  
 Indirect challenges, including allergen and mannitol, which are associated with 
airway hyperresponsiveness are also associated with airway inflammation [Van den 
Berge et al., 2001;Van Velzen et al., 1996]. Even though both methacholine and mannitol 
are bronchoprovocation challenges, airway hyperresponsiveness is more sensitive to 
methacholine than mannitol and mannitol is associated more with airway inflammation 
than methacholine Allergen challenges are also associated with airway inflammation. 
Airway inflammation is directly correlated with FENO measurements. Increased 
production of nitric oxide and the recruitment of eosinophils occur together and are key 
characteristic features of inflammation in asthma. Moreover, the high values of FENO 
(≥20 ppb) suggest underlying inflammation. As such, the high FENO values should 
correlate with a positive mannitol test. This was evident in about 90% of participants 
having a positive mannitol response. Even though there were no significant differences 
in FE NO between all the baseline FENO visits, the participants who had ≥ 35ppb, had no 
significant differences in FENO across all the baseline FENO visits. Participants with a 
likely eosinophilic inflammation confirmed by a positive mannitol test did not have a 
significant change in baseline FENO across all the visits in our study. This could mean 
that the participants had a stable amount of inflammation. A similar amount of ongoing 
inflammation could also be supported by figure 3.3 showing that the allergen challenges 
on both the methacholine and mannitol arms were similar. 
Our original hypothesis was that the change in airway responsiveness to mannitol  
might increase more than that of methacholine; however, our results showed otherwise. 
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 Another phenomena associated with indirect challenges that need to be taken into 
account are refractoriness and cross refractoriness. Refractoriness has been 
documented in hyperventilation induced asthma [Rakotosihanaka et al., 1986], repeated 
challenges of adenosine 5’ monophosphate challenge, [Daxun et al., 1989]  and repeated 
challenges with mannitol [Suh et al., 2011]. Refractoriness has also been documented in 
hypertonic airway challenges and exercise induced bronchoconstriction [Belcher et al., 
1987]. The common ground that all these challenges share is that they are all indirect 
stimuli to bronchoconstriction. Although the exact mechanism of refractoriness is 
unknown, it has been reported that there is cross-refractoriness between EIB (osmolar 
indirect stimuli) and leukotriene D4 (LTD4) [Manning et al., 1993]. There is a potential for 
cross refractoriness between indirect stimuli, which could also help explain cross 
refractoriness between allergen challenges and mannitol challenges, if they shared a 
common pathway. It is also worth mentioning that, refractoriness may not have been 
caused by depletion of mast cells, but rather, desensitization of leukotriene receptors and 
the release of inhibitory prostaglandins. [Manning et al., 1993;   Larsson et al., 2011; 
Larsson et al., 2013]. 
Allergen induced inflammation can be seen in people with a late asthmatic 
response. Another possibility why the study failed to support our hypothesis was that, we 
did not select for atopic asthmatics with an LAR. The increase in airway responsiveness 
to methacholine (direct challenges) following allergen challenge is present in almost all 
atopic asthmatics irrespective of having an LAR or not. Traditionally, people with an LAR 
also have an EAR; hence, the interchangeable use of LAR and DAR. Nevertheless, 
people with an EAR do not necessarily have an LAR. Furthermore, the time allowed post 
allergen might not have been enough to see the LAR which is usually maximal about 7 
hours post allergen. We looked however at 3 hours post  allergen, which is a timepoint at 
which the airway responsiveness to direct stimuli has been previously shown to 
significantly increase.   
In the three-hour study, there were no significant differences between all the 
baseline FENO measurements across all visits. This could mean that even though 
inflammation could be occurring three hours after the allergen challenge, the three hours 
might not be enough to see a surge in the amount of eosinophils indicative of underlying 
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 inflammation. One could assert that three hours might not be enough to observe a change 
in inflammation. This assertion was also supported by the fact that the entire baselines 
FEV1 across all the visits were not significantly different from each other. In an instance 
where the FENO values did not accurately capture the amount of inflammation, the 
baseline FEV1 values across all the visits show that, there were no significant changes in 
the airway diameter. 
It will be necessary that we study the allergen-induced increase in both direct and 
indirect challenges at twenty-four hours post allergen inhalation. Although the three hour 
duration after allergen challenge has been enough to observe an increase in 
responsiveness to methacholine, the three hour time point has not be established as 
long enough to see an increase in responsiveness to indirect stimuli. Moreover, an 
indirect stimuli like mannitol might need more time than three hours to mount an 
expected increase in airway response. Indirect stimuli do not attach directly to airway 
smooth muscles rather, they prompt the release of subsequent mediators from mast 
cells and basophils to cause bronchoconstriction. This whole process might need more 
than three hours to see its full effect. In addition, we believe twenty-four hours post 
allergen challenge will be enough to see the LAR, and how it will affect the indirect 
challenges. Furthermore, the participants in the future study should have an LAR and 
the measurement of FENO should be made at critical time-points in order to follow the 
changes in ongoing inflammation during the study. A future study should include more 
asthma subjects as a smaller sample size might not accurately capture the asthma 
population in the geographic area where the research is conducted. Asthma is a 
heterogeneous disease therefore it will also be beneficial to group asthmatic subjects 
into specific populations in research study for example late asthmatic responders, EIB 
subjects, AHR subjects. Having a categorized research subjects can help clarify the 
possible interactions and between the stimuli and the participants for example allergen 
induced change in airway responsiveness to mannitol in late asthmatic responders, EIB 
subjects and e.t.c.   
42 
 
 3.9.   Results for twenty-four-hour study.  
3.9.1.   Participants. 
All participants were provided with, and signed, a University of Saskatchewan 
Biomedical Research Ethics Board consent form before commencing the study. 
Thirteen participants (male or female) screened for the study; however only eleven 
participants aged between 19 and 37 completed testing successfully without any 
incidence of adverse effects. The participants had an allergic response to at least one of 
the allergens used in the lab, which mainly included cat, house dust mite, and grass. 
The participants had a clinical diagnosis of mild atopic asthma at some point in their 
lives. Participants were asked to refrain from corticosteroids about four weeks before 
the start of the study, and refrain from short acting bronchodilators 6 hours before any 
study visit. The mean baseline FEV1 of all participants at the start of the study was 
3.53L ± 0.25 SD and greater than 70% predicted. 
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Table 3.10. The demographics of all participants in the twenty-four hour study. 
 
 
 
 *Allergen concentration was not completely inhaled for two minutes due 20% fall in FEV1 from the baseline for safety 
reasons.  
** House dust mite dermatophagoides pteronyssinus 
***House dust mite dermatophagoides farinae 
 
 
 
 
Participant Sex Age(years) 
Baseline 
FEV1 (L) 
Baseline 
FEV1 (% 
predicted) 
Height 
(cm) 
Weight 
(kg) Allergen 
Skin Test 
Endpoint 
Concentration 
Inhaled  
1 M 28 4.71 96 185 85 Cat 1:128 *1:4 
2 M 37 3.54 82 178 86 Cat 1:128 1:64 
3 F 27 2.74 88 160 47 **HDM-DP 1:2048 1:64 
4 M 29 4.57 99 180 81 Grass 1:4096 1:64 
5 F 23 3.19 93 168 87 ***HDM-DF 1:8192 *1:64 
6 F 30 2.24 77 160 82 Grass 1:16384 1:1024 
7 F 22 4.04 101 180 61 HDM-DF 1:256 1:256 
8 M 21 4.57 93 183 80 Cat 1:256 *1:8 
9 F 26 3.01 101 155 54 Cat 1:2048 1:16 
10 F 19 3.06 97 157 54 Cat 1:512 1:8 
11 F 22 3.13 89 168 61 Cat 1:128 1:16 
Mean   26±1.6 3.53±0.25 92.4±2.3 170±3.4 71±4.6    
 
 
 3.9.2.   Allergen challenge 
Figure 3.4 shows the changes in FEV1 for both the methacholine arm and mannitol 
arm up to 7 hours following allergen exposure. The raw data is presented in Tables 3.11 
and 3.12 for methacholine and mannitol respectively. There were no significant 
differences (p > 0.4) in mean fall in FEV1 at any time point between the methacholine and 
mannitol arms. 
3.9.3.   Methacholine Challenge 
The geometric mean methacholine PC20 before allergen was 5.9 mg/ml ± 0.23 SE 
The geometric mean methacholine PC20 after allergen was 2.2 mg/ml ± 0.19 SE. The 
decrease was statistically significant (p= 0.01). Figure 3.5.  
3.9.4.   Mannitol challenge 
The geometric mean dose response ratio for mannitol before allergen was 63 mg 
/∆% FEV1 ± 0.15 SE. The geometric mean dose response ratio for mannitol after allergen 
was 158 mg /∆%FEV1  ± 0.19 SE. The increase was statistically significant (p = 0.03). 
Figure 3.6 shows the individual changes in the dose response ratio before and after 
allergen challenge. All data, including log transformations are shown in the table 3.13.
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Table 3.11. Percentage fall in FEV1 in the methacholine arm following allergen inhalation in the 24-hour post 
allergen study. 
Participan
t 
%∆FEV
1 @ 
10m 
%∆FEV
1 @ 
20m 
%∆FEV
1 @ 
30m 
%∆FEV
1 @ 
45m 
%∆FEV
1 @ 
60m 
%∆FEV
1 @ 
90m 
%∆FEV
1 @ 
120m 
%∆FEV
1 @ 
180m 
%∆FEV
1 @ 
240m 
%∆FEV
1 @ 
300m 
%∆FEV
1 @ 
360m 
%∆FEV
1 @ 
420m 
1 17.5 18.9 20.7 16.3 12.2 4 1.3 -4.7 0.0 1.3 10.0 8.2 
2 30.2 37.6 37.1 35.3 28.7 21.8 13.2 5.7 8.0 5.5 10.1 14.1 
3 14.2 22.4 22.4 19.7 16.3 4.7 13.2 9.8 14.2 3.1 -0.7 1.0 
4 17.3 19.5 23.0 15.8 8.3 6.8 3.9 1.3 5.5 7.9 14.4 17.3 
5 26.5 15.6 13.7 4.0 1.6 -0.9 -0.6 0.6 2.2 6.9 9.7 10.9 
6 28.3 35.8 24.7 14.0 11.2 0.9 -8.4 -8.4 -12.1 -7.0 -1.9 6.0 
7 29.8 23.6 19.6 16.5 19.9 11.5 7.1 2.6 3.7 -0.5 0.0 3.1 
8 21.4 22.5 17.9 14.2 11.4 6.3 4.8 2.8 0.2 1.5 3.1 3.5 
9 21.7 25.7 27.6 11.8 9.2 8.6 5.3 3.3 2.9 8.2 6.3 8.6 
10 28.1 23.7 18.4 6.4 3 -0.3 -2 -3.3 -5.7 -6.4 -6.0 -5.7 
11 7.80 13.3 4.90 2.90 -0.3 -2.9 -1.9 -2.3 1.6 -1.9 -2.6 -1.6 
Mean 
±SD 
22.1 ± 
6.9 
23.5 ± 
7.1 
20.9 ± 
7.7 
14.3 ± 
8.5 
11.0 ± 
8.0 
5.5 ± 
6.6 
3.3 ± 
2.0 
0.7 ± 
1.5 
1.9 ± 
2.1 
1.7 ± 
1.6 
3.9 ± 
2.0 
5.9 ± 
2.1 
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Table 3.12.  Percentages fall in FEV1 in the mannitol arm following allergen inhalation in the 24-hour study. 
Participant 
%∆FEV1 
@ 10m 
%∆FEV1 
@ 20m 
%∆FEV1 
@ 30m 
%∆FEV1 
@ 45m 
%∆FEV1 
@ 60m 
%∆FEV1 
@ 90m 
%∆FEV1 
@ 120m 
%∆FEV1 
@ 180m 
%∆FEV1 
@ 240m 
%∆FEV1 
@ 300m 
%∆FEV1 
@ 360m 
%∆FEV1 
@ 420m 
1 13.5 12.0 10.7 5.9 2.6 -1.3 -2.4 -4.9 -2.4 -3.8 -2.4 -1.3 
2 22.2 22.2 22.5 18.4 9.3 2.6 0.6 2.3 0.0 4.7 4.9 3.5 
3 20.4 14.2 18.3 18.7 6.6 6.9 5.5 5.2 4.2 4.5 4.8 3.5 
4 38.0 37.3 27.0 22.9 20.2 14.9 10.11 12.3 18.2 27.9 27.9 24.7 
5 32.3 11.1 12.0 8.9 3.8 -0.6 -0.9 -1.3 3.5 4.7 9.8 6.6 
6 6.2 10.6 5.3 9.3 -1.8 -8.8 -8.8 -10.6 -11.1 -6.2 -3.5 7.5 
7 11.8 34.5 39.0 14.4 5.5 4.3 5.8 5.3 4.8 12.8 3.8 2.0 
8 25.5 21.1 17.0 16.3 8.3 4.6 1.3 0.0 0.4 0.4 2.2 4.6 
9 17.0 15.0 11.7 6.7 2.3 0.0 -2.0 -3.3 0.3 1.7 2.3 3.7 
10 20.9 19.7 17.2 11.1 10.8 4.9 4.3 0.9 0.6 5.5 5.8 7.1 
11 27.7 34.2 29.5 20.5 12.7 4.8 4.8 -3.4 -3.8 -1.0 -3.4 -2.7 
Mean±SE 
21.4 ± 
2.8 
21.1 ± 
3.0 
19.1 ± 
2.9 
13.9 ± 
1.8 
7.3 ± 
1.8 
2.9 ± 
1.8 
1.7 ± 
1.6 
0.2 ± 
1.8 
1.3 ± 
2.2 
4.7 ± 
2.8 
4.7 ± 
2.6 
5.4 ± 
2.2 
 
 
 
 
 
 
 48 
Time in minutes
0 60 120 180 240 300 360 420
% 
 ∆  
Fa
ll i
n F
EV
1
-25
-20
-15
-10
-5
0
Allergen-induced fall in FEV1 in the methacholine arm
Allergen-induced fall in FEV1 in the mannitol arm
 
Figure 3.4. Allergen-induced FEV1 fall in all the participants grouped into the methacholine and mannitol arm in 
the 24-hour study. 
.
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Table 3.13. Changes in PC20 in methacholine and dose response ratio in mannitol before and after allergen 
challenge in the 24-hour study. 
Participan
t 
MCh PC20 Man Dose response Methacholine Mannitol 
PRE 
ALLERGE
N 
POST 
ALLERGE
N 
PRE 
ALLERGE
N 
% FEV1 
FALL 
POST 
ALLERGE
N 
% FEV1 
FALL 
Log 
MCh 
pre 
Log 
MCh 
post 
Log 
DR 
pre 
Log 
DR 
post 
1 
5.5 3.0 635 3.0 635 13.2 0.7404 0.4771 2.3010 1.6778 
2 
1.1 0.3 315 22.2 315 15.5 0.0414 -0.5376 1.1549 1.3098 
3 
1.2 1.0 635 5.2 635 4.7 0.0792 0.0170 2.0969 2.1549 
4 
73.0 27 635 1.8 635 1.1 1.8633 1.4314 2.5229 3.0000 
5 
1.6 2.6 155 19.4 635 21.5 0.2041 0.4150 0.9031 1.4685 
6 
0.2 0.3 475 18.6 635 10.6 -0.6197 -0.6021 1.4089 1.7696 
7 
14.2 5.3 635 12.6 635 0.8 1.7559 0.9294 1.6990 3.0000 
8 
57.0 8.5 635 16.4 635 7.7 1.1847 -0.2757 1.5850 1.9208 
9 
15.3 0.53 635 13.0 635 3.4 1.1523 0.7243 1.6990 2.3010 
10 
12.6 8.0 635 9.1 635 0.7 1.1004 0.8633 1.8539 3.0000 
11 
9.9 1.9 635 5.1 635 4.0 0.9956 0.2788 2.0969 2.2219 
Geometric mean ± SE 5.9±0.20 2.2±0.23 63±0.15 158±0.18 
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Figure 3.5. A graph showing the decrease in methacholine PC20 before and after 
the allergen challenge in the twenty-four hour study. The vertical axis is a log scale.  
Individual data points are geometric means ± S.E. 
n = 11, p = 0.01 
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Figure 3.6. A graph showing the mannitol dose response slope before and after 
allergen challenge in the 24-hour study. The vertical axis is a dose in mg per 
percent change in FEV1 scale. Individual data points are geometric means ± S.E. 
n = 11, p = 0.03 
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 3.9.4.   Baseline FEV1.  
Baseline lung function was assessed at each visit using the highest of reproducible 
spirometric maneuvers. Twenty-four hours after the allergen challenge on the 
methacholine arm, the baseline FEV1 was significantly lower than both the twenty-four 
hour pre allergen FEV1 and the immediate pre allergen FEV1 ( p < 0.05). Conversely, 
there were no differences between baseline FEV1 values during mannitol allergen 
mannitol testing (p > 0.05). Table 3.14 shows all the baselines FEV1 (L) raw data 
 
Table 3.14. Baseline FEV1 (L) raw data   
Participant 
Methacholine Mannitol 
24H-Pre 
allergen 
Pre 
Allergen 
Post 
Allergen 
24H-Pre 
allergen 
Pre 
Allergen 
Post 
Allergen 
1 4.57 4.49 4.44 4.71 4.68 4.8 
2 3.54 3.48 3.23 3.52 3.42 3.43 
3 2.77 2.95 2.67 2.74 2.89 2.77 
4 4.58 4.57 3.85 4.54 4.45 3.57 
5 3.13 3.21 3.05 3.19 3.16 3.02 
6 2.24 2.15 1.62 2.49 2.26 3.49 
7 3.89 3.82 3.51 3.97 3.97 3.80 
8 4.63 4.57 4.22 4.46 4.59 4.58 
9 3.01 3.04 2.74 2.95 3.00 2.94 
10 3.16 2.99 3.00 3.05 3.25 2.86 
11 3.08 3.08 3.01 2.96 2.92 3.00 
Mean ± 
SE 3.51±0.24 3.50±0.24 3.21±0.23 3.51±0.24 3.51±0.24 3.48±0.21 
3.9.6.   Fractional Exhaled Nitric Oxide in methacholine arm. 
Geometric mean FENO levels across methacholine triad testing were 27, 26, 37, 
and 55 ppb. There was a significant difference after both the 7-hour post allergen FENO 
level and 24-hour post allergen FENO level (p < 0.05) Table 3.15 shows the FENO 
measurements on methacholine arm in all the participants. Figure 3.7 shows the FENO 
measurements on methacholine arm in all participants.  
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 Table 3.15.  Fractional Exhaled Nitric Oxide measurements on methacholine arm 
 
Participant 
number  
24-hour  
Pre  
Allergen 
Pre 
Allergen 
7 hour  
Post 
Allergen 
24 hour  
 Post 
 Allergen 
1 58 54 56 90 
2 47 52 47 63 
3 19 19 *EF *EF 
4 21 20 21 76 
5 44 47 57 108 
6 34 30 28 29 
7 9 9.7 *EF *EF 
8 72 65 86 96 
9 19 19 21 32 
10 12 9 *EF 54 
11 21 19 22 21 
Geometric Mean 
(ppb) ±SE 
27 ± 0.09  26 ± 0.09 37 ± 0.09 55 ± 0.10 
 
* Equipment failure. 
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Figure 3.7 Nitric oxide measurement on methacholine arm before allergen 
challenge, 7-hour and 24-hour time points after allergen challenge in the 24 hour 
study. 
3.9.7.   Fractional Exhaled Nitric Oxide in mannitol arm. 
Geometric mean FENO across the mannitol arm were 29, 31, 39 and 39 ppb. 
There was no significant difference after both the 7 hour post allergen FENO level and 
24 hour post allergen FENO level (p = 0.05). 
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 Table 3.16 shows the FENO measurements on mannitol arm in all the 
participants. Figure 3.8 shows the FENO measurement on mannitol arm in all 
participants. 
 
Table 3. 16. Fractional Exhaled Nitric Oxide measurements on mannitol arm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Equipment failure 
Participant 
24-hour 
Pre 
Allergen 
Pre 
Allergen 
7 hour 
Post 
Allergen 
24 hour  
Post 
Allergen 
1 24 29 39 63 
2 37 47 51 70 
3 13 10 17 21 
4 106 62 68 57 
5 53 67 61 96 
6 16 22 17 15 
7 20 21 24 21 
8 58 61 78 93 
9 33 40 42 40 
10 32 *EF *EF 28 
11 8 13 *EF 20 
Geometric 
Mean(ppb)±SE 29±0.10 31±0.09 39±0.08 39±0.09 
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Figure 3.8.   Nitric oxide measurements on mannitol arm before allergen challenge, 
7-hour and 24-hour post allergen time points in the 24 hour study. 
3.10.    Discussion for 24-hour study. 
In the 24-hour study, we again found an increase in airway response to 
methacholine and a decrease in airway response to mannitol. The increase in airway 
responsiveness to methacholine was associated with an increase in FENO. However, 
FENO did not increase after allergen in the mannitol arm. According to the literature, the 
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 increase in airway responsiveness to methacholine tends to occur in those with an LAR 
[Cockcroft et al., 1977; Cartier et al., 1982]. In our study, the majority of the participants 
did not have an LAR (i.e. a 15% drop in FEV1).Only one person had a fall in FEV1 of 
more than 15% in the three to seven hours after allergen challenge. This documents a 
dissociation between LAR and an increase in hyperresponsiveness to methacholine.  
It is possible that if airway inflammation increased and an LAR was present, that airway 
responsiveness to mannitol would occur. We had hoped for a large percentage of LAR 
responders in our sample but unfortunately only one participant met LAR criteria. This 
participant did not respond to mannitol even in the presence of an LAR.  
One potential limitation was not requiring a positive response to mannitol at study 
entry. We had anticipated that participants who were initially negative with mannitol 
would convert to a positive mannitol challenge. This however was not the case and as a 
result, we calculated a dose response ratio (cumulative dose [635mg]/ %∆FEV1) instead 
of a mannitol PD15. 
Sputum eosinophilia tends to increase after allergen challenge, which correlates 
with LAR [De Monchy et al., 1985].Additionally, airway responsiveness to indirect 
stimuli, correlates with airway inflammation [Van den Berge et al., 2001]. We assessed 
airway inflammation by measuring FENO. We found that allergen challenge increased 
airway inflammation in the methacholine arm and this was associated with an increase 
in airway responsiveness to methacholine.  
The increase in allergen–induced airway inflammation in the mannitol arm was 
borderline not significant. However if the participants had an LAR and a positive 
mannitol response, one could speculate that the increase in allergen-induced airway 
inflammation would be significant. This suggests airway response to mannitol may have 
increased if the extent of airway inflammation was greater. It may be worth mentioning 
that, the relationship between allergen–induced airway eosinophilia and allergen–
induced airway responsiveness is not clear-cut in terms of what causes or proceeds the 
other [Leckie et al., 2000].  
In order to help explain the decrease in airway response to mannitol, we turned 
our focus on refractoriness and cross-refractoriness which are well-recognized 
phenomena, when dealing with indirect stimuli challenges [Schoeffel et al., 1980; 
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 Rakotosihanaka et al., 1986; Daxun et al., 1989; Suh et al., 2011;Belcher et al., 1987]. 
Although the specifics of the mechanism of refractoriness is also unclear, it has been 
established that, repeated inhalation of mannitol within 90 minutes induces 
refractoriness, at the airway smooth muscle’s responsiveness to mediators of 
bronchoconstriction, rather than the depletion of mast cell mediators [Larsson et al., 
2011] . A later time point (i.e. 24 hours) should be enough time for the mast cell to 
manufacture and repackage mediators of inflammation.  
Moving on from the amount of mediator release, another possible explanation is 
airway receptor desensitization of the mast cell at the site of the airway smooth muscle. 
[Kern et al., 1986]. Among the potential receptors that are desensitized to the mediators 
are leukotriene receptors in the airway smooth muscle. This is evident from 
desensitization to aspirin challenge in aspirin-intolerant asthma, associated with 
decreased expression of leukotriene receptors [Sousa et al., 2002]. Again, 24-hour post 
allergen time should allow the airway smooth muscle cell to recover from sensitization. 
It has been established that following repeated exercise within 2 hours, about half of 
asthmatics will have less than half of the initial response. This is observed with yet 
another unclear mechanism of bronchoconstriction via indirect stimuli, which primarily 
affects the osmolarity of the airways, similar to mannitol.  
Another reason is the protective response of mast cell mediators [Larsson et al., 
2011] that accounts for the decrease in airway responsiveness to mannitol following 
allergen exposure. Since the release of mediators has been confirmed by an increase in 
nitric oxide measurements, one can assume that different mediators that offer protection 
to the airway smooth muscle in response to an allergen and subsequent mannitol 
challenges are also released. These “airway smooth muscle protection mediators” result 
in the less responsiveness of the airway smooth muscle 3-hour post allergen and 24- 
hour post allergen. Moreover, the activation of cysteinyl-leukotrienes receptors cause a 
dose dependent secondary release of prostaglandins and other cyclooxygenase 
products in the lungs [Dahlen, 1983; Omini et al., 1981]. Among these prostaglandins 
are the bronchoprotective PGE2. This is evident in the fact that premedication with 
cyclooxygenase inhibitors such as indomethacin attenuates the refractoriness following 
exercise challenge [O’Byrne et al., 1986].  
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 According to Larsson et al., not only is an increase in mast cell mediator release, 
but also a more sustained elevation of mediator excretion from refractory participants 
within 90 minutes of repeated mannitol inhalation. This was more pronounced for LTE4 
mediators. Cross-refractoriness exists between EIB, which is an osmolar indirect 
stimulus and LTD4, when both challenges are done one hour apart. [Manning et al., 
1993].The refractoriness to LTD4 was abolished by the cyclooxygenase inhibitor, 
proving the involvement of leukotrienes and prostaglandins in refractoriness to repeated 
exercise challenge in interdependent pathways. 
In conclusion, airway responsiveness to methacholine increased twenty-four 
hours after allergen challenge however airway response to mannitol was decreased. 
Even though there was enough time between the allergen challenge and the mannitol 
challenge to rule out refractoriness, the response to mannitol was similar to that of the 
three-hour study. This opens up questions about the mechanisms of indirect stimuli; 
airway inflammation, allergen challenge and how it differs from that of direct stimuli. 
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 4. GENERAL DISCUSSION AND FUTURE RESEARCH 
Increase in methacholine responsiveness has been documented as early as three hours 
however, methacholine responsiveness is routinely measured at twenty-four hours post 
allergen. [Cockcroft et al., 1977]. Not much is known about allergen-induced change in 
airway responsiveness to mannitol. We looked at the change in mannitol 
responsiveness at three hours and twenty-four hours post allergen. In the three-hour 
post allergen study, we found that, there was an increase in airway responsiveness to 
methacholine (i.e. a decrease in PC20) Airway responsiveness to mannitol however, 
decreased (i.e. an increase in PD15) at 3 hours post allergen which was the complete 
opposite of what we hypothesized. A potential explanation was refractoriness, a 
phenomenon associated with indirect stimuli (e.g. EIB). This led us to extend the time 
between allergen challenge and mannitol challenge from three hours to twenty-four 
hours. Again, however methacholine responsiveness increased and mannitol 
responsiveness decreased twenty-four hours post allergen challenge.  
We expected a greater response to mannitol than methacholine because airway 
responsiveness to indirect stimuli correlates better with airway inflammation than the 
direct stimuli. Both an increase in AHR to methacholine and an increase in airway 
inflammation are associated with allergen exposure. We assessed changes in airway 
inflammation in the twenty-four hour study by measuring FENO. We found that FENO 
increased significantly in the methacholine arm but not significantly in the mannitol arm. 
We believe our hypotheses were valid and our methodologies to test our 
hypotheses were sound. We assumed however that people with a negative mannitol 
challenge would potentially shift to positive following allergen challenge. This did not 
occur and the absence of mannitol responsiveness at study entry could be a limitation. 
Notably however, airway responsiveness to mannitol was significantly decreased and 
not just absent. 
Twenty four hour post allergen challenge measurements and the utility of the 
allergen challenge model is usually employed for assessing mechanisms of asthma and 
novel drug treatments for asthma in dual responders. Ideally, the majority of our 
participants in the twenty-four hour study would have included late responders. This 
however was not the case. There was only one participant who had a fall in FEV1 of 
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 greater than or equal to 15% in the three to seven hours post allergen. Interestingly, this 
participant did have an increase in airway responsiveness to methacholine but not to 
mannitol. It is hard to draw conclusions from one out of eleven participants however; we 
should acknowledge the data generated by this individual.  
With respect to airway inflammation, we measured baseline airway inflammation 
in the three-hour study prior to testing at each visit. The increased FENO values are 
indicative of underlying airway inflammation, which suggested all participants should 
have tested positive for mannitol. 
 In the 24-hour study, there was an increase in FENO after allergen challenge in 
the methacholine arm but not in the mannitol arm. This suggests that twenty-four hours 
is enough to observe the recruitment of inflammatory cells and therefore an increase in 
airway inflammation, which supports the potential for an increase in airway 
responsiveness to mannitol. There was a significant increase between the FENO levels 
at 7 and 24 hours in the methacholine. However, there were no significant difference 
between the seven and 24-hour time points of FENO in the mannitol arm. The increase 
in FENO at 24 hours in the methacholine arm is consistent with the literature for both 
increased airway inflammation and subsequent increase in airway responsiveness to 
methacholine. Interestingly, airway inflammation in the mannitol arm did not increase 
and there was an associated decrease in airway responsiveness to mannitol.  
Our hypotheses were driven by  the observation of Van den Berge et al. that, the 
AMP PC20 was more closely related to airway inflammation than methacholine PC20 
[Van den Berge et al., 2001]. AMP is a known indirect stimulus of airway 
hyperresponsiveness; as such, we made the jump from AMP to mannitol. The 
assumption was due to the fact that they both are indirect stimuli, and they possibly 
share a similar pathway with the various indirect stimuli of bronchoconstriction namely 
allergen, EIB, AMP, and mannitol. The sharing of a common pathway was unveiled 
mostly in the studying of refractoriness across indirect stimuli [Schoeffel et al., 1980; 
Rakotosihanaka et al., 1986; Daxun et al., 1989; Suh et al., 2011; Belcher et al., 1987]. 
Since we associate greater airway inflammation with indirect challenges (that is AMP) 
[Van den Berge et al., 2001] by way of LAR, we generalized that airway responsiveness 
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 to mannitol challenge test post allergen should be higher than methacholine challenge 
test post allergen.  
The nature of the 3-hour post allergen study did not accommodate the detection of late 
asthmatic responders, due to the administering of either the mannitol or the 
methacholine challenge at the 3-hour post allergen time, and controlling the 
bronchoconstriction with medication at the end of the study. There was not enough time 
to detect the LAR, which is mostly associated with inflammation. However, the 24-hour 
post allergen study took this into consideration and waited for the LAR before 
administering either the mannitol or the methacholine challenge. The 24-hour post 
allergen study also resulted in a negative mannitol challenge. Moreover, the dose 
response ratio of the mannitol increased twenty-four hours after allergen challenge. 
Even though FENO measurements increased, the dose response ratio of mannitol 
increased instead of decreasing. The LAR has been seen mostly in indirect challenges. 
Allergen challenge is classified as an indirect stimulus. Allergen-induced LAR is a 
phenomenon well understood; however, the emergence of exercise-induced LAR is a 
rare but possible phenomenon considered under heavy criticism. There seems to be an 
emergence of indirect stimuli induced LAR. The interaction of these LAR’s is also 
another possible explanation as to why mannitol response decreased following allergen 
challenge. Even though there are heavy criticisms surrounding the presence of indirect 
stimuli’s LAR aside from allergen induced LARs, future research is called for into the 
mechanisms of LARs, and the different LARs interactions among indirect stimuli. 
At this point, we can stand by our hypothesis and attribute the decrease in airway 
response to mannitol to a lack of LAR in participants, refractoriness, cross 
refractoriness, absence of airway inflammation and desensitization of leukotriene 
receptors. We can also refute our hypothesis and pin it on the unknown pathway that 
indirect stimuli ‘supposedly’ share. The various indirect stimuli might not necessarily act 
in the same manner whenever they are thrown together in asthma challenges. It might 
also not be wise to substitute the behavior of one indirect stimulus for another indirect 
stimulus although; all indirect stimuli seem to have a better correlation with airway 
inflammation than their direct counterparts do. This calls for further research on the 
degree of correlation between all the various indirect stimuli and airway inflammation. 
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 Research questions should be aimed at finding a possible interaction between allergen 
challenges and mannitol or AMP. Allergen is classified as an indirect challenge hence 
future research should be aimed at any possible interference between the allergen and 
indirect stimuli. This could be further investigated by looking at allergen induced late 
response, exercised induced late response and mannitol induced late response. In the 
case of establishing the existence of a late response with each of the indirect stimuli, 
one should look at the type of asthma subjects. Moreover, one should also keep a 
curious eye on people who are not consistent to a type of bronchoprovocation stimulus. 
These participants usually test positive for a stimulus and later on (in a year) test 
negative for that same stimulus. Research efforts should be geared toward finding out 
why there are inconsistencies in response to bronchoprovocation stimulus occurring in 
research participants along the years. Shedding light on these could help answer 
research questions about why there is an increase and a decrease in response to direct 
and indirect stimulus respectively. Further research is also needed on the impacts of 
allergen challenges on the various indirect stimuli namely EIB, AMP and mannitol. The 
supposed pathway that indirect stimuli share should be uncovered at least in terms of 
what is common to all indirect stimulus if not all. Knowing their pathways can help 
scientists conduct research to eliminate possible refractoriness and cross-refractoriness 
in further studies.  
Although the term asthma is sometimes used loosely to describe EIB or EIA, 
AHR, allergen induced bronchoconstriction. Research efforts should be made at 
classifying these categories. The results of allergen induced increase in airway 
response to mannitol in EIB participants might not be the same as that in subjects with 
AHR. As such, the research criteria for participants should be aimed at selecting 
individuals with AHR only or EIB only or EIA only and not a participant with both. This 
classification should help researchers answer questions on the behavior of 
bronchoprovocation stimuli in a specific group of research participants.  
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